The present disclosure application relates to cannabis-containing compositions comprising at least one cannabinoid, provided in a gel formulation. The compositions may include cannabidiol. The source of the cannabidioid may be cannabis, a cannabis extract, or an industrial hemp oil extract. Methods of treating and/or reducing symptoms of an inflammatory response and/or inflammation are described, comprising administering to a subject in need thereof the disclosed compositions.

A composition comprising a hydrogen peroxide source and at least one salicylate. Preferably, the hydrogen peroxide source comprises hydrogen peroxide and a means for generating hydrogen peroxide.

Provided herein are compositions including methylene bis[4,4′-(2-chlorophenylureidophenoxyisobutyric acid)] (LR-90) or a pharmaceutically acceptable salt or derivative thereof and methods of use thereof for treating and/or preventing chemotherapy-induced neuropathic pain in a subject in need thereof.

Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of relapsed or refractory acute myeloid leukemia or high-risk myelodysplastic syndrome using a pyrazolylpyrimidine, e.g., a compound of Formula (I).

##STR00001##

The present disclosure provides a feed additive for domesticated animals that is capable of increasing feed performance, as well as associated methods for promoting growth and zootechnical performance in domesticated animals. The animal feed additive provided contains Total Lignans standardized in the contents of Furoguaiacin-like compounds and Guaiacin-like compounds. The present disclosure also describes methods for improving growth via the dietary inclusion of Total Lignans standardized in Furoguaiacin-like compounds and Guaiacin-like compounds.

The present invention is a device and method for making Cannabis infused edibles comprising: a flow chamber having an inlet and an outlet, and configured to open; a porous material placed inside said flow chamber to form a tortuous flow path; a Cannabis burning chamber to burn Cannabis and generate a Cannabis smoke and a circulation system to circulate the Cannabis smoke in and out of the flow chamber. In operation one or more porous material are placed inside the flow chamber and infused with Cannabis smoke. The smoke passes continuously through the porous of said porous material and the resin of the smoke remains in the porous of the porous material; thereby produces a porous material which is smoke-resin infused for the purpose of consumption by means other than in-hailing smoke which is more convenient for consumers and has all the beneficial effects of Cannabis compounds.

The disclosure relates to methods for treating or preventing an Insomnia Disorder by administering to a human in need thereof a compound of formula (I), or a compound of formula (IA), (IB), or (IC), or a solvate thereof, in a daily dose of from about 0.5 mg to about 6.0 mg. In certain embodiments, such compounds effectively treat or prevent an Insomnia Disorder in the animal, while producing reduced side effects compared to previously available compounds. ##STR00001##

The present invention relates to a construct comprising a C13 to C27 fatty acid non-covalently bound to a hydrophobic region of a carrier particle, methods of manufacture, and uses thereof.

The presently disclosed subject matter relates to a composition and method of using the composition for oral delivery of a bioactive agent to a subject. More particularly, the presently disclosed subject matter relates to a composition comprising an effective amount of at least one bioactive agent layered over a substrate and a method of reducing zoonotic infectious disease by administering the composition to a subject. The presently disclosed subject matter further relates to a method of preparing the composition.

Use of 5-methyltetrahydrofolate in preparing a medicine or health-care food for preventing neonatal congenital heart disease in peri-pregnancy and/or pregnant women has an effect of preventing congenital heart disease. The prophylactic dosage of the 5-methyltetrahydrofolate can be greater than 1 mg. Compared with synthetic folic acid, high-dose use has no teratogenic effect. Thus the 5-methyltetrahydrofolate can prevent birth defects in a high dose and can be used for preventing neonatal congenital heart disease.